Wolverine Trading
HZNP

Wolverine Trading’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wolverine Trading’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,700
Closed -$279K – 5325
2023
Q2 		$279K Sell
2,700
-1,000
-27% -$106K ﹤0.01% 3181
2023
Q1 		$404K Sell
3,700
-35,200
-90% -$3.89M ﹤0.01% 2715
2022
Q4 		$4.43M Buy
+38,900
New +$3.23M 0.01% 961
2022
Q3 		– Sell
-11,800
Closed -$974K – 5699
2022
Q2 		$974K Buy
11,800
+1,700
+17% +$161K ﹤0.01% 1950
2022
Q1 		$1.07M Sell
10,100
-8,300
-45% -$809K ﹤0.01% 2369
2021
Q4 		$1.99M Sell
18,400
-14,100
-43% -$1.54M ﹤0.01% 1900
2021
Q3 		$3.57M Buy
32,500
+12,900
+66% +$1.34M ﹤0.01% 1572
2021
Q2 		$1.86M Sell
19,600
-11,300
-37% -$1.04M ﹤0.01% 2065
2021
Q1 		$2.69M Sell
30,900
-10,200
-25% -$861K ﹤0.01% 1646
2020
Q4 		$2.97M Buy
41,100
+9,000
+28% +$669K ﹤0.01% 1408
2020
Q3 		$2.51M Buy
32,100
+15,300
+91% +$1.05M 0.01% 1310
2020
Q2 		$929K Sell
16,800
-5,400
-24% -$231K ﹤0.01% 2078
2020
Q1 		$652K Sell
22,200
-11,900
-35% -$403K ﹤0.01% 2370
2019
Q4 		$1.23M Sell
34,100
-3,000
-8% -$92K ﹤0.01% 2217
2019
Q3 		$1.02M Sell
37,100
-17,800
-32% -$460K ﹤0.01% 1966
2019
Q2 		$1.32M Buy
+54,900
New +$1.39M ﹤0.01% 1812
2019
Q1 		– Sell
-42,400
Closed -$823K – 5693
2018
Q4 		$823K Sell
42,400
-40,300
-49% -$790K ﹤0.01% 2151
2018
Q3 		$1.62M Buy
82,700
+40,500
+96% +$770K ﹤0.01% 1876
2018
Q2 		$599K Hold
42,200
– – ﹤0.01% 2850
2018
Q1 		$599K Sell
42,200
-20,500
-33% -$303K ﹤0.01% 2850
2017
Q4 		$915K Buy
62,700
+4,200
+7% +$59K ﹤0.01% 2319
2017
Q3 		$742K Buy
58,500
+43,200
+282% +$549K ﹤0.01% 2183
2017
Q2 		$181K Sell
15,300
-24,600
-62% -$306K ﹤0.01% 3652
2017
Q1 		$599K Sell
39,900
-81,800
-67% -$1.32M ﹤0.01% 2187
2016
Q4 		$1.97M Buy
121,700
+19,300
+19% +$350K 0.01% 1347
2016
Q3 		$1.82M Buy
102,400
+42,500
+71% +$830K 0.01% 1375
2016
Q2 		$1M Buy
+59,900
New +$969K 0.01% 1596

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wolverine Trading's HZNP Position: Q3 2022 in Review

Wolverine Trading sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 4,854 shares — an estimated $400K sold.

Wolverine Trading first reported a position in HZNP in Q2 2016 and held it in 21 quarters. The position peaked at $2.64M in Q3 2020. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Wolverine Trading reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Wolverine Trading sold 4,854 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $400K.
  • Wolverine Trading first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 21 quarters.
  • Wolverine Trading's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.64M in Q3 2020.
  • 529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.